Press release
Odense, Denmark – July 20, 2026 – Inverna Therapeutics is pleased to announce its participation in the 26th Annual Biotech in Europe Forum (BEF) on the 7th – 8th of October 2026 in Basel. The event will be part of the Sachs Autumn Life Sciences Week (#SALSW), which will also incorporate the 1st Annual European Healthcare Impact Summit (#Sachs_EHIS), taking place the day before BEF.
“Our recent advancements position Inverna to actively pursue strategic partnerships and fundraising opportunities and we look forward to connecting with partners and investors to share our scientific progress, vision and growth strategy at this global partnering and investment event.”
said Poul Sørensen, CEO of Inverna Therapeutics.
Inverna’s CEO Poul Sørensen welcomes meeting requests through the respective partnering platforms.
About Inverna Therapeutics
Inverna Therapeutics is a Danish biotech company, founded in 2024 emerging from Southern Danish University in Odense, nurtured by Argobio Studio, a launch platform for Europe’s best medicinal science. With our proprietary drug discovery platform, we’re dedicated to developing transformative RNA therapeutics based on precision RNA splicing modulation. Our unique technology allows us to design, test, and develop highly specific activators of pseudo-exons in disease-relevant target RNA. Today, we are pursuing breakthroughs in neurological disorders such as Parkinson’s disease, somatic repeat expansion diseases, and Huntington’s disease, knowing that the approach can extend to other organ systems and diseases.
Contact :
- Poul Sørensen, CEO of Inverna Therapeutics
- psorensen@invernatx.com
